Neoplasms

All Conditions

Blood and Lymph Conditions

Symptoms and General Pathology

Digestive System Diseases

Carcinoma

Thrombocytopenia

Recurrence

Colorectal Neoplasms

Disease Attributes

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Colonic Diseases

Intestinal Diseases

Rectal Diseases

Blood Platelet Disorders

Hematologic Diseases

Cytopenia

Antineoplastic Agents

All Drugs and Chemicals

Micronutrients

Hematinics

Vitamins

Irinotecan

Raltitrexed

Oprelvekin

Topoisomerase I Inhibitors

Enzyme Inhibitors

Antimetabolites

Folic Acid

Vitamin B Complex

Folic Acid Antagonists

Folinic Acid

Folate

Vitamin B9

rhTPO: 300 u/kg, subcutaneous injection, per day. (stopped as soon as the platelet count rises to normal)

Concurrent Chemoradiotherapy:

Radiation: judged according to the tumor site and radiotherapy purpose.

Irinotecan: 80 mg/m2 (UGT1A1\*28 6/6) or 65 mg/m2 (UGT1A1\*28 6/7)

Raltitrexed: 3 mg/m2 q3w

rhIL-11: 50 ug/kg, subcutaneous injection, per day. (stopped as soon as the platelet count rises to normal)

Concurrent Chemoradiotherapy:

Radiation: judged according to the tumor site and radiotherapy purpose.

Irinotecan: 80 mg/m2 (UGT1A1\*28 6/6) or 65 mg/m2 (UGT1A1\*28 6/7)

Raltitrexed: 3 mg/m2 q3w

rhTPO 300u/kg, subcutaneous injection, qd

rhTPO

80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7)

irinotecan

in the use of intensity-modulated radiotherapy (IMRT) technology, the dose is judged according to the tumor site and radiotherapy purpose.

radiotherapy

rhIL-11 50ug/kg, subcutaneous injection, qd

rhIL-11

Ji Zhu, MD

Zhen Zhang, MD

This randomized controlled clinical phase II study was designed to compare the effect of rhTPO with rhIL-11 in improving thrombocytopenia in patients with recurrent colorectal cancer who underwent radiotherapy and with thrombocytopenia.

Most patients with recurrent CRC have undergone a six-month postoperative adjuvant chemotherapy with oxaliplatin plus fluorouracil. Although the main dose-limiting side effect of oxaliplatin is neurotoxicity, with the widespread use of this drug, there are more and more reports that oxaliplatin is discontinued because of thrombocytopenia, which increases the risk of bleeding, rate of blood transfusion needs and length of stay. On the other hand, patients undergoing pelvic radiotherapy may also experience significant bone marrow suppression because flat bones such as the tibia may be exposed to high doses radiation. Low platelet counts is an urgent problem to be solved in order to give adequate quantitative radiotherapy. This randomized controlled clinical phase II study was designed to compare the effect of rhTPO with rhIL-11 in improving thrombocytopenia in patients with recurrent colorectal cancer who underwent radiotherapy and with thrombocytopenia, thus providing more evidence in clinical practice.

Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia

A Randomized Phase II Study of Recombinant Human Thrombopoietin (Rh-TPO) and Recombinant Human Interleukin-11 (rhIL-11) for Recurrent Colorectal Cancer (CRC) Patients With Thrombocytopenia

pathological complete response (pCR) was defined no viable cancer cell under the examination of surgical resection specimen.

Fudan University

professor

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia	NCT03823079	Recurrent Color... Thrombopenia	rhTPO irinotecan Raltitrexed radiotherapy rhIL-11	18 Years - 75 Years	Fudan University
Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia	NCT03823079	Recurrent Color... Thrombopenia	rhTPO irinotecan Raltitrexed radiotherapy rhIL-11	18 Years - 75 Years	Fudan University

Spots Global Cancer Trial Database for thrombopenia

Every month we try and update this database with for thrombopenia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.